Skip to main content
Clinical Trials/NCT01088841
NCT01088841
Completed
Phase 1

The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY

University Hospital, Basel, Switzerland1 site in 1 country16 target enrollmentApril 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Appetite and General Nutritional Disorders
Sponsor
University Hospital, Basel, Switzerland
Enrollment
16
Locations
1
Primary Endpoint
Gastrointestinal peptide secretion
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gut.

Detailed Description

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors in glucose stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion of 75 g glucose with different concentrations of lactisole (150 ppm, 300 ppm and 450 ppm)in a double blind, 4-way crossover trial including 16 healthy subjects.

Registry
clinicaltrials.gov
Start Date
April 2009
End Date
March 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
University Hospital, Basel, Switzerland

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects
  • BMI of 19.0-24.5
  • Age 18-40
  • stable body weight for at least 3 month

Exclusion Criteria

  • substance abuse
  • regular intake of medication
  • medical or psychiatric illness
  • gastrointestinal disorders or food allergies

Outcomes

Primary Outcomes

Gastrointestinal peptide secretion

Time Frame: 2 hours blood sampling

Study Sites (1)

Loading locations...

Similar Trials